PAIN 4406Comment on Tramer et al.

References 

1. Czernichow P, Hochain P, Nousbaum JB, Raymond JM, Rudelli A, Dupas JL, et al. Epidemiology and course of acute upper gastrointestinal haemorrhage in four French geographical areas. Eur J Gastroenterol Hepatol. 2000;12:175–181
   • MEDLINE
2. Guess HA, West R, Strand LM, Helston D, Lydick EG, Bergman U, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan Canada 1983. J Chin Epidemiol. 1988;41:35–45
3. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta- analysis. Br Med J. 1996;312:1563–1566
4. Moore N, Vuillemin N, Abiteboul M, Boudignat O, Paliwoda A, Robin J, et al. Large-scale safety study of Ketoprofen 25 mg (Toprec^®) in febrile and painful conditions. Pharmacoepidemiol Drug Safety. 1996;5:292–302
5. Moore N, Van Ganse E, Le Parc J, Wall R, Schneid H, Farhan M, et al. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. A large scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest. 1999;18:89–98
6. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85:169–182
   • Abstract
   • Full Text
   • Full-Text PDF (180 KB)